Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide

作者：Bao MS; Zhang Y; Wan M; Dai L; Hu XP; Wu XL; Wang L; Deng P; Wang JZ; Chen JZ; Liu YJ; Yu YL^*; Wang LY

来源：Clinical Immunology, 2006, 118(2-3): 180-187.

DOI：10.1016/j.clim.2005.09.014

• CpG ODN
• SARS-CoV
• anit-virus
• PBMCs
• pDCs
• B cells
• NK cells
• IFN-alpha
• IFN-gamma

To develop CpG oligodeoxynucleotides (CpG ODNs) based therapy for prevention and treatment of severe acute respiratory syndrome (SARS), we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' and tested for its anti-SARS-CoV activity. We found that the supernatants of human PBMCs stimulated by BW001 significantly protected Vero cells from SARS-CoV infection. BW001 could stimulate human PBMCs and pDCs to secrete high level of IFN-alpha and promote human PBMCs and B cells to proliferate. Furthermore, we demonstrated that BW001 could activate CD19(+) B cells and CD56(+) NK cells in human PBMCs. In addition, BW001 could enhance NK cytotoxicity and IFN-gamma secretion in human PBMCs. Together, BW001 represents a novel type of CpG ODN and may have potential for the development of treatment and prevention for SARS as well as other viral associated diseases.

• 出版日期2006-3
• 单位吉林大学